Conversely, it was associated with a higher incidence of adverse effects compared to ARB therapy alone.242 According to that, the prospect of targeting (P)RR in the treatment of hypertension is not as good as AT1R. This evidence concerns the gene AGTR1 and hypertensive disorder.